A Phase 1 interventional study of placebo cream and Glyceryl Trinitrate in Raynaud's Phenomenon, sponsored by Procris Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2008-12-30.
Sponsored by Procris Pharmaceuticals · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Raynaud Disease with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Raynaud Disease · United States.
Among the 33 studies in Raynaud Disease with a site in United States, this one is the 28th largest by planned enrollment, is one of 2 that started in 2008, is one of 3 in phase 1, and was the 11th registered.
81 studies on the registry are indexed under Raynaud Disease; 8 are open to participants now.
Browse Raynaud Disease studies →2 of the 33 studies in Raynaud Disease with a site in United States are open now. Recruiting first, the newest first:
Brigham and Women's Hospital · Sites in United States
Ages 18+
Robyn T. Domsic, MD, MPH · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Raynaud Disease studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 10 · Phase 3 9 · Phase 4 5
First in 2001; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 30 across 67 interventional studies indexed under Raynaud Disease.
Median enrollment 34 across the 33 interventional studies. Of the 28 that completed or were terminated, 14 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 33 have an industry lead sponsor. The 10 most frequent:
Procris Pharmaceuticals is the lead sponsor of 2 studies on the registry; none are open to participants now.
Procris Pharmaceuticals has 1 study filed under Raynaud Disease — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 33 studies in Raynaud Disease with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the blood flow response to topical Glyceryl Trinitrate when applied to the skin of patient's fingers with Raynaud's Phenomenon.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
placebo cream applied to 2 adjacent fingers on non-dominant hand one time
Drug: placebo cream
0.6mg of Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand
Drug: Glyceryl Trinitrate
1.2mg of Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
Drug: Glyceryl Trinitrate
1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers on non-dominant hand one time
Drug: Glyceryl Trinitrate
2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
Drug: Glyceryl Trinitrate
placebo cream applied to 2 adjacent fingers of non-dominant hand one time
0.6mg of Glyceryl Trinitrate applied to 2 adjacent fingers on non-dominant hand one time
1.2mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
Investigate vascular responses to topical Glyceryl Trinitrate versus placebo in patients with Raynaud's using laser Doppler imaging to measure blood flow
Time frame: 6 visits no less than 10 hours between visits
Evaluate the dose proportionality of the microvascular response to topical Glyceryl Trinitrate
Time frame: 6 visits no less than 10 hours between visits
Compare the systemic versus topical effect of Glyceryl Trinitrate on vascular response.
Time frame: 6 visits no less than 10 hours between visits
The record gives a start of Jun 2008, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nitroglycerin
Procris Pharmaceuticals